Systematic review of ablative therapy for the treatment of renal allograft neoplasms

Table 4 Summary of the different ablative therapies described in the case reports and the case series examined¹

Variables	Range or Number
	RFA	CA	HIFU		MWA	IRE
Procedures	78	15	3		3	1
Patients	70	15	3		3	1
Tumor size (mm)	5-40	15-35	8-55		21-28	16
Tumor histology
Clear cell	10	7	1		1	1
Papillary	41	3	2		2	0
Mixed RCC	0	1	0		0	0
Chromophobe	2	0	0		0	0
Tubulo-papillary	2	0	0		0	0
Tubulo-cystic	1	0	0		0	0
RCC NOS	17	0	0		0	0
Oncocytoma	0	1	0		0	0
Indeterminate	0	1	0		0	0
Not available	5	2	0		0	0
Interventional access
Percutaneous	67	8	3		2	1
Open	0	1	0		0	0
Laparoscopic	0	1	0		0	0
Transosseous	0	0	0		1	0
Not available	11	5	0		0	0
Guidance modality
US	24	4	3		0	0
CT	12	4	0		3	1
MRI	0	1	0		0	0
US and CT	18	1	0		0	0
Not available	24	5	0		0	0
Primary treatment failure	2	0	1		0	0
Re-treatment failure	0	-	1		-	-
Recurrence	1	0	0		0	0
Disease-specific mortality	0	0	0		0	0
Renal allograft loss	5	0	0		0	0
Complications	8	2	0		1	0
Follow-up (mo)	3-71	1-59	12-81		8-61	34

¹Summaries based on individual cases should not be considered as an estimate of the “real world”. RCC: Renal cell carcinoma; NOS: Not otherwise specified; US: Ultrasound; CT: Computed tomography; MRI: Magnetic resonance imaging.